Cat. #156497
HEK293DeltaNDUFS2 Cell Line
Cat. #: 156497
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Disease: Leighs
Model: Knock-Out
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Abey Bandara
Institute: Virginia Tech
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: HEK293DeltaNDUFS2 Cell Line
- Alternate name: HEK293?NDUFS2
- Research fields: Apoptosis and autophagy;Drug development;Metabolism
- Tool sub type: Continuous
- Parental cell: HEK293
- Organism: Human
- Disease: Leighs
- Growth properties: The mutant grows much slower than the parent cell line. The doubling time of the mutant is 3 times higher than that of the parent cell line.
- Model: Knock-Out
- Description: The HEK293?NDUFS2 cell line expresses a CRISPR/Cas9 mutated NDUFS2, shown to significantly alter the function of complex I (CI) of the mitochondrial electron transport chain. This NDUFS2 mutant cell line displays disruptions to NDUFS2 that mimic isolated complex I deficiency and can be used as a powerful model of several types of mitochondrial disease. Specific disruptions in the NDUFS2 gene have been reported to present clinically as the following disease conditions:-Leigh syndrome-Cardiomyopathy -Encephalomyopathy -Miscellaneous: basal ganglia and brainstem lesions, seizures, hypotonia, neonatal hypotonia, amaurosis, nystagmus, dysmorphic features, epilepsy and signs of brainstem involvement, and lactic acidosis.
- Production details: The cell line is currently stored at Virginia Tech. By culturing approximately 1 million frozen cells in growth media, approximately 40 million cells can be harvested in a two weeks time.
- Additional notes: CRISPR edited HEK293 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can prov...
- Recommended controls: HEK293 parent line
Target Details
- Target: NDUFS2
Applications
- Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...
Handling
- Format: Frozen
- Growth medium: DMEM medium supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin at 37?°C temperature and 5-6% CO2.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Mycoplasma free: Yes
Related Tools
- Related tools: Mitochondrial complex II mutated SDHD cell line
References
- Bandara et al. 2021. Mitochondrion. 58:160-168. PMID: 33744462.
